Literature DB >> 26921389

Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny.

Nicholas L Giebel1, Jeffrey D Shadley1, D Gail McCarver1, Kenneth Dorko1, Roberto Gramignoli1, Stephen C Strom1, Ke Yan1, Pippa M Simpson1, Ronald N Hines2.   

Abstract

Variability in drug-metabolizing enzyme developmental trajectories contributes to interindividual differences in susceptibility to chemical toxicity and adverse drug reactions, particularly in the first years of life. Factors linked to these interindividual differences are largely unknown, but molecular mechanisms regulating ontogeny are likely involved. To evaluate chromatin structure dynamics as a likely contributing mechanism, age-dependent changes in modified and variant histone occupancy were evaluated within known CYP3A4 and 3A7 regulatory domains. Chromatin immunoprecipitation using fetal or postnatal human hepatocyte chromatin pools followed by quantitative polymerase chain reaction DNA amplification was used to determine relative chromatin occupancy by modified and variant histones. Chromatin structure representing a poised transcriptional state (bivalent chromatin), indicated by the occupancy by modified histones associated with both active and repressed transcription, was observed for CYP3A4 and most 3A7 regulatory regions in both postnatal and fetal livers. However, the CYP3A4 regulatory regions had significantly greater occupancy by modified histones associated with repressed transcription in the fetal liver. Conversely, some modified histones associated with active transcription exhibited greater occupancy in the postnatal liver. CYP3A7 regulatory regions also had significantly greater occupancy by modified histones associated with repressed transcription in the fetus. The observed occupancy by modified histones is consistent with chromatin structural dynamics contributing to CYP3A4 ontogeny, although the data are less conclusive regarding CYP3A7. Interpretation of the latter data may be confounded by cell-type heterogeneity in the fetal liver.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26921389      PMCID: PMC4931893          DOI: 10.1124/dmd.116.069344

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  49 in total

Review 1.  Charting histone modifications and the functional organization of mammalian genomes.

Authors:  Vicky W Zhou; Alon Goren; Bradley E Bernstein
Journal:  Nat Rev Genet       Date:  2010-11-30       Impact factor: 53.242

2.  Nucleosome stability mediated by histone variants H3.3 and H2A.Z.

Authors:  Chunyuan Jin; Gary Felsenfeld
Journal:  Genes Dev       Date:  2007-06-15       Impact factor: 11.361

3.  Combinatorial patterns of histone acetylations and methylations in the human genome.

Authors:  Zhibin Wang; Chongzhi Zang; Jeffrey A Rosenfeld; Dustin E Schones; Artem Barski; Suresh Cuddapah; Kairong Cui; Tae-Young Roh; Weiqun Peng; Michael Q Zhang; Keji Zhao
Journal:  Nat Genet       Date:  2008-06-15       Impact factor: 38.330

Review 4.  Liver-enriched transcription factors and hepatocyte differentiation.

Authors:  S Cereghini
Journal:  FASEB J       Date:  1996-02       Impact factor: 5.191

Review 5.  Signals and combinatorial functions of histone modifications.

Authors:  Tamaki Suganuma; Jerry L Workman
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

6.  PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.

Authors:  Kathrin Klein; Maria Thomas; Stefan Winter; Andreas K Nussler; Mikko Niemi; Matthias Schwab; Ulrich M Zanger
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

Review 7.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction.

Authors:  Marcella Martignoni; Geny M M Groothuis; Ruben de Kanter
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

Review 8.  Modification of enhancer chromatin: what, how, and why?

Authors:  Eliezer Calo; Joanna Wysocka
Journal:  Mol Cell       Date:  2013-03-07       Impact factor: 17.970

Review 9.  The ontogeny of drug metabolism enzymes and implications for adverse drug events.

Authors:  Ronald N Hines
Journal:  Pharmacol Ther       Date:  2008-03-05       Impact factor: 12.310

10.  Standardisation of data from real-time quantitative PCR methods - evaluation of outliers and comparison of calibration curves.

Authors:  Malcolm J Burns; Gavin J Nixon; Carole A Foy; Neil Harris
Journal:  BMC Biotechnol       Date:  2005-12-07       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.